A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects
Study Details
- Bronchiectasis
- Cystic Fibrosis
- Drug: CHF6333 (Part 1 - SAD)
- Drug: Placebo (Part 1 - SAD)
- Drug: CHF6333 (Part 2 - MAD)
- Drug: Placebo (Part 2 - MAD)
- Male subjects aged 18-55 years
- BMI between 18-30 kg/m2
- Non smokers
- Lung function above 80% of predicted normal value
- Healthy subjects based on medical evaluation including medical history, physical examination, laboratory tests and cardiac testing
- Any clinically relevant abnormalities and/or uncontrolled diseases
- Abnormal laboratory values
- Recent respiratory tract infection
- Hypersensitivity to the drug or excipients
- Positive serology results
- Positive cotinine, alcohol, drug of abuse tests
- Unsuitable veins for repeated venepuncture
Protocol Summary
Human Neutrophil Elastase (HNE) plays a pivotal role in innate immunity and in neutrophilic lung inflammation that characterized many diseases. CHF 6333 is a potent and 24h-durable inhibitor of HNE, developed as Dry Powder Inhaler (DPI) formulation. This study is designed to investigate the tolerability, safety and pharmacokinetics of inhaled CHF6333 DPI in healthy male subjects.
The study will comprise two parts:
Part 1 will consist of two alternated cohorts of healthy male subjects to assess the safety, tolerability and pharmacokinetics of Single Ascending Dose (SAD) of CHF6333.
Part 2 will consist of four sequential cohorts of healthy male subjects to assess the safety, tolerability and pharmacokinetics of Multiple Ascending Dose (MAD) of CHF6333